<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442168</url>
  </required_header>
  <id_info>
    <org_study_id>Sevuparin/DF02_TSM02</org_study_id>
    <nct_id>NCT01442168</nct_id>
  </id_info>
  <brief_title>Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria</brief_title>
  <official_title>A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Modus Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Modus Therapeutics AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the tolerability and pharmacokinetics of
      Sevuparin/DF02 when administered as an i.v. infusion in combination with Malanil®
      (atovaquone/proguanil) as anti-malarial treatment in subjects affected with uncomplicated
      malaria. The study will also assess the potential of Sevupatin/DF02 to reduce infected
      erythrocyte sequestration and rosette formation.

      The study consists of a dose escalation part (part 1) followed by an open labelled,
      randomized comparison of treatment with Sevuparin/DF02 and Malanil® versus Malanil® alone
      (part 2).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities according to specified criteria</measure>
    <time_frame>During treatment and 14 days post treatment follow-up.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve of late stage peripheral blood parasitemia over time (Part 2).</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Malaria, Falciparum</condition>
  <arm_group>
    <arm_group_label>Sevuparin/DF02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevuparin/DF02 plus anti-malarial regimen (Malanil®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anti-malarial regimen (Malanil®) alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevuparin sodium + atovaquone/proquanil</intervention_name>
    <description>Sevuparin 4 times per day and malanil according to label</description>
    <arm_group_label>Sevuparin/DF02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atovaquone/proquanil</intervention_name>
    <description>malanil according to label</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of acute uncomplicated P. falciparum malaria, confirmed by positive blood
             smear with asexual forms of a single species (P. falciparum)

          -  Counts of asexual forms of P. falciparum: 10 000- 100 000/ul with or without
             gametocytaemia

          -  Presence of fever defined as &gt; 38°C tympanic temperature or a history of fever within
             the last 24 hours

        Exclusion Criteria:

          -  Mixed infection with other Plasmodium species

          -  Any criteria of severe or complicated malaria as defined by the WHO, 2010

          -  Use of high doses aspirin (more than 100 mg/day) or dual anti-platelet therapy or use
             of heparin,Low Molecular Weight Heparin (LMWH) or warfarin

          -  Presence of significant anemia as defined by Hb &lt;8 g/dL or Hct &lt; 25%

          -  A platelet count &lt; 50,000/μL

          -  Presence of febrile conditions caused by diseases other than malaria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Leitgeb, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Modus Therapeutics AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mae Ramat Hospital</name>
      <address>
        <city>Mae Ramat</city>
        <state>Tak province</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maesot General hospital</name>
      <address>
        <city>Mae Sot</city>
        <state>Tak Province</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Tropical Diseases</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uncomplicated Falciparum Malaria</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>Antimalarial treatment</keyword>
  <keyword>Sevuparin/DF02</keyword>
  <keyword>Adjuvant therapy</keyword>
  <keyword>Malanil</keyword>
  <keyword>Peripheral blood parasitemia</keyword>
  <keyword>Rosette formation</keyword>
  <keyword>Maximum tolerated dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atovaquone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

